Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

Sep. 18, 2024 — A team of scientists alarmed by the loss of biodiversity across the world due to climate change has proposed a new approach to managing vulnerable ... Rugged Falklands Landscape ...

The African Initiative spreads misleading claims online and promotes Russian culture on the ground. Social media firms are accused of stoking the disorder in the UK but have not commented on it ...

RAHWAY, N.J. - Merck (NS:PROR) & Co., Inc. (NYSE: MRK), also known as MSD outside the United States and Canada, has announced the acquisition of CN201, a clinical-stage bispecific antibody, from Curon ...

In a noteworthy business move, Merck acquired CN201, a clinical-stage bispecific antibody, from Curon Biopharmaceutical for $700 million. The European Commission has also approved Merck's therapy, ...

In a recent development, Merck announced the acquisition of “CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases.” The acquisition ...

Under the terms of the deal, Merck will buy full global rights to CN201 for an upfront cash payment of $700m. Curon is also eligible to receive up to $600m in milestone payments associated with ...

Republican Donald Trump is running for president for a third time. Here's what you need to know about him. Long before Donald Trump became US president, he was "The Donald", a celebrity and ...